The founder of hundreds of billions of pharmaceutical companies topped Asia's richest man!

Medical Network, March 3 News On March 2, the Hurun Research Institute released the "2021 Hurun Global Rich List".
Tesla's Elon Musk became the world's richest man for the first time, with a total wealth of RMB 1.
28 trillion
.
The richest man in Asia is the "King of Bottled Water".
The 67-year-old Zhong Sui Sui, ranked seventh with a fortune of 550 billion yuan, has also become the first Chinese entrepreneur to enter the top ten of the world's richest list
.
Affected by the new crown epidemic, biotechnology is one of the fastest-growing industries in the past year, and the number of billion-dollar entrepreneurs in the health industry has increased significantly
.
Ranked No.
1 in the big health industry is Chen Bang, the founder of Aier Ophthalmology.
The list shows that the wealth of 56-year-old Chen Bang tripled last year to 170 billion yuan
.
Followed by the Jiang Rensheng family of Zhifei Biology and Mindray's Li Xiting and Xu Hang
.
Thanks to the rapid growth of Hansen and Hengrui Medicine, the total wealth of Sun Piaoyang and Zhong Huijuan increased by more than 50% to 280 billion yuan
.
The deadline for calculating the wealth of the top 100 entrepreneurs in the "Hurun Global Rich List 2021"-medical and health-related entrepreneurs is January 15, 2021
.

　　Zhong Sui-sui became the richest man in Asia.
The
　　market value of Wantai Biotech exceeded 100 billion.
The
list shows that a total of 3,228 billion-dollar entrepreneurs from 2402 companies from 68 countries are on the list this year
.
Affected by the new crown epidemic, this year's wealth increase is the largest in the past decade
.
The total wealth of global billion-dollar entrepreneurs increased by 32% over last year, reaching RMB 95 trillion
.
The world added 412 billion-dollar entrepreneurs, a record high
.
China added 259 billion-dollar entrepreneurs, a total of 1,058, and became the first country in the world to have 1,000 known billion-dollar entrepreneurs, surpassing the three countries that followed the United States, India and Germany.
Sum
.
"King of Bottled Water", 67-year-old Zhong Suansui became the first Chinese entrepreneur to enter the top ten of the global rich list with a fortune of 550 billion yuan, ranking seventh.
Zhong Suansui also replaced India’s Mukesh.
Ambani became the richest man in Asia
.
This is due to the listing of Nongfu Spring in Hong Kong in September last year
.
Zhong Sui Sui also founded another listed company-vaccine manufacturer Wantai Bio, with a current market value of more than 10 billion U.
S.
dollars, making him one of the few entrepreneurs in the world who has founded more than one company worth more than 10 billion U.
S.
dollars.
One
.
Since its listing in April last year, Wantai Bio has achieved an annual increase of 1499%, ranking second in the A-share increase list
.
As of March 2, Wantai Bio's total market value exceeded RMB 100 billion
.
It is understood that Wantai Bio has the world's third, China's first and only bivalent cervical cancer vaccine approved for marketing
.
During the outbreak of the new crown pneumonia epidemic, Wantai Bio also launched a self-developed new crown pneumonia virus detection reagent
.
At the same time, Wantai Bio's nine-valent HPV vaccine has entered phase III clinical trials
.
In addition, China accounts for 66% of the global self-made female billion-dollar entrepreneurs, led by Hansen Pharmaceutical’s 60-year-old Zhong Huijuan, with a wealth of 150 billion yuan
.
The 53-year-old Ou Leiqiang, the founder of BeiGene, who focuses on the research and development of anti-cancer drugs, is the richest non-Chinese living in mainland China.
His wealth has more than doubled from last year to 21.
5 billion yuan
.

　　The health industry is newly listed as the 33 richest people.
In
2020, the health industry is the fastest rising industry, with manufacturers of vaccines, medical equipment and personal protective equipment performing strongly
.
From China's point of view, among the emerging industries, the second largest number of people on the list also comes from the health industry, with 86, an increase of 33 from last year
.
Ranked first in the industry is Chen Bang of Aier Ophthalmology, followed by the Jiang Rensheng family of Zhifei Biology and Li Xiting and Xu Hang of Mindray.

.
The list shows that the 56-year-old Chen Bang from Aier Ophthalmology has tripled his wealth to 170 billion yuan
.
The wealth of the 68-year-old Jiang Rensheng of Zhifei Biology has tripled to 170 billion yuan
.
Zhifei Bio is mainly engaged in the research and development, production, sales, promotion, distribution and import and export of vaccines and biological products.
It is also the designated agency of Merck in China to uniformly sell all the vaccines imported by Merck
.
The 2020 annual performance report released by Zhifei Biological showed that the total operating income was 15.
19 billion yuan, a year-on-year increase of 43.
48%; the net profit attributable to shareholders of listed companies was 3.
3 billion yuan, a year-on-year increase of 39.
47%
.
At present, the new coronavirus vaccine that Zhifei participated in the research and development has entered phase III clinical trials
.
In addition, products such as tetravalent influenza virus split vaccine and tetravalent recombinant norovirus vaccine are also in clinical trials
.
In 2020, the medical device sector will be equally hot .
Mindray’s Li Xiting and Xu Hang’s wealth have each more than doubled to 150 billion yuan
.
As a "leading" enterprise in domestic medical equipment , Mindray's main business covers three major areas of life information and support, in vitro diagnostics, and medical imaging, and its market share of monitors, ventilators, anesthesia machines, defibrillators and other products Ranked among the top at home and abroad
.
The third quarter report of 2020 shows that from January to September, Mindray Medical achieved revenue of 16.
064 billion yuan, a year-on-year increase of 29.
76%; net profit was 5.
363 billion yuan, a year-on-year increase of 46.
09%, surpassing the entire year of 2019
.
In addition, thanks to the rapid growth of Hansen and Hengrui Medicine , the total wealth of Sun Piaoyang and Zhong Huijuan increased by more than 50% to 280 billion yuan
.
Hengrui is a well-known supplier of anti-tumor drugs, surgical drugs and contrast agents in China
.
In recent years, Hengrui Pharmaceutical’s R&D investment accounted for about 17% of sales.
In the first three quarters of 2020, a total of 3.
34 billion yuan has been invested in R&D funds, accounting for 17.
2% of sales revenue
.
Henry currently has a variety of innovative products to market, including Ka Ruili natalizumab, fluorine azole Palley, pyrrole imatinib, apatinib, sulfur and other training filgrastim
.
Some institutions predict that the peak sales of carrelizumab are expected to exceed tens of billions
.
Hansen Pharmaceutical's product line layout covers the treatment of major diseases such as anti-tumor, central nervous system, anti-infection and diabetes, with more than one hundred research projects
.
In 2020, Hansen's Class 1 new drug Ametinib mesylate will be launched.
It is the world's third third-generation EGFR inhibitor independently developed by Hansen and the first domestically-made third-generation EGFR inhibitor
.